Advertisement
Research ArticleChemotherapy, Antibiotics, and Gene Therapy
Open Access

Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites

De Lin, Rumen Kostov, Jeffrey T.-J. Huang, Colin J. Henderson and C. Roland Wolf
Journal of Pharmacology and Experimental Therapeutics October 2017, 363 (1) 12-19; DOI: https://doi.org/10.1124/jpet.117.243246

Abstract

Ponatinib, a pan-BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML), causes severe side effects including vascular occlusions, pancreatitis, and liver toxicity, although the underlying mechanisms remain unclear. Modifications of critical proteins through reactive metabolites are thought to be responsible for a number of adverse drug reactions. In vitro metabolite screening of ponatinib with human liver microsomes and glutathione revealed unambiguous signals of ponatinib-glutathione (P-GSH) adducts. Further profiling of human cytochrome P450 (P450) indicated that CYP1A1 was the predominant P450 enzyme driving this reaction. P-GSH conjugate formation paralleled the disappearance of hydroxylated ponatinib metabolites, suggesting the initial reaction was epoxide generation. Mouse glutathione S-transferase p1 (mGstp1) further enhanced P-GSH adduct formation in vitro. Ponatinib pharmacokinetics were determined in vivo in wild-type (WT) mice and mice humanized for CYP1A1/2 and treated with the CYP1A1 inducers 2,3,7,8-tetrachlorodibenzodioxin or 3-methylcholanthrene. Ponatinib exposure was significantly decreased in treated mice compared with controls (7.7- and 2.2-fold for WT and humanized CYP1A1/2, respectively). Interestingly, the P-GSH conjugate was only found in the feces of CYP1A1-induced mice, but not in control animals. Protein adducts were also identified by liquid chromatography–tandem mass spectrometry analysis of mGstp1 tryptic digests. These results indicate that not only could CYP1A1 be involved in ponatinib disposition, which has not been previously reported, but also that electrophilic intermediates resulting from CYP1A1 metabolism in normal tissues may contribute to ponatinib toxicity. These data are consistent with a recent report that CML patients who smoke are at greater risk of disease progression and premature death.

Introduction

Ponatinib (Iclusig) is an orally available pan-BCR-ABL tyrosine kinase inhibitor that has been approved for treatment of resistant chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Zhou et al., 2011; Cortes et al., 2012; Razzak, 2013; Miller et al., 2014). Ponatinib was structurally designed with a carbon-carbon triple-bond linkage to target the T315I mutation (BCR-ABLT315I), which confers resistance to other approved tyrosine kinase inhibitors (O’Hare et al., 2009; Huang et al., 2010). Ponatinib has high efficacy against multiple resistant forms, including T315I mutation in a phase I clinical trial of ponatinib in refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Cortes et al., 2012) and T315I tyrosine kinase inhibitor–resistant CML cells (O’Hare et al., 2009). However, serious side effects have been reported; thrombocytopenia (in 37% of patients) and neutropenia (19%) are the most common hematologic events of ponatinib treatment (Cortes et al., 2012). Hepatotoxicity has also been reported, including alanine aminotransferase and aspartate aminotransferase elevation in patients in clinical trials (10.5% and 8.2%, respectively). Cardiovascular toxicity, including both arterial and venous thromboembolism and severe systemic hypertension, and dose-limiting toxic effects limit its broad application in clinic (Frankfurt and Licht, 2013; ARIAD Pharmaceuticals, Cambridge, MA, 2014 Iclusig package insert). However, the mechanism of ponatinib toxicity remains unclear.

The metabolic profile of ponatinib has been evaluated in preclinical studies. The disposition of ponatinib is a result of both esterase/amidase activity to an inactive carboxylic acid (AP24600) and metabolism by the cytochrome P450 (P450)–dependent monooxygenase system [ARIAD Pharmaceuticals, 2013 Iclusig (ponatinib) tablets for oral use: prescribing information (http://wwwaccessdatafdagov/drugsatfda_docs/label/2013/203469s007s008lblpdf); Narasimhan et al., 2013]. Ponatinib is metabolized by P450 CYP3A4 (and to a lesser extent by CYP3A5, CYP2C8, and CYP2D6) to N-oxide and N-desmethyl metabolites, the latter being 4-fold less potent than ponatinib. Although the hydrolysis of ponatinib has been reported to be the major pathway of disposition, a recent study showed that concurrent therapy with ponatinib and ketoconazole (a CYP3A4 inhibitor) significantly increased the ponatinib area under the curve (AUC) AUC0–∞ and AUC0–t values and the Cmax values (Narasimhan et al., 2013).

Levels of drug exposure, as well as the generation of chemically reactive metabolites, can play a major role in drug side effects (Baillie, 2006; Kalgutkar and Dalvie, 2015). To investigate this possibility, we carried out a detailed analysis of ponatinib metabolism in a panel of purified recombinant human P450 enzymes. In addition to identifying CYP3A4 as a major pathway of ponatinib disposition (Narasimhan et al., 2013), we have also found that CYP1A1, an inducible enzyme in tissues such as lung and lung tumors, is highly active toward this compound. Intriguingly, metabolism by CYP1A1 resulted in the formation of an electrophilic metabolite, which formed a glutathione (GSH) conjugate in a reaction catalyzed by the glutathione S-transferases (GSTs). The significance of these data in relation to the efficacy and side effects of ponatinib is discussed.

Materials and Methods

Chemicals and Reagents.

All reagents, unless otherwise stated, were purchased from Sigma-Aldrich (Poole, United Kingdom). NADPH was obtained from Melford Laboratories (Ipswich, United Kingdom), ponatinib was purchased from LC Laboratories (Woburn, MA), and 2,3,7,8-tetrachlorodibenzodioxin (TCDD) was purchased from Toronto Research Chemicals (Toronto, Canada). The Nanosep centrifugal device with Omega ultrafiltration membrane molecular weight cutoff of 10 kDa was obtained from Pall Corporation (East Hills, NY).

Animal Lines and Husbandry.

The generation and characterization of hCYP1A1/1A2 mice will be described elsewhere (manuscript in preparation). All animals were maintained under standard animal house conditions, with free access to food (RM1 diet; Special Diet Services, Essex, United Kingdom) and water, and a 12-hour light/12-hour dark cycle. All animal work was carried in accordance with the Animal Scientific Procedures Act (1986), as amended by European Union Directive 2010/63/EU, and after local ethical review.

Subcellular Fractionation.

Livers were harvested, excised, and snap frozen in liquid nitrogen for storage at −80°C until processing. Briefly, a small piece (∼200 µg) in three volumes of KCl-phosphate buffer (10 mM KHPO4, 20 mM EDTA, and 150 mM KCl, pH 7.4) was homogenized (POLYTRON PT 2100; Kinematica, Lucerne, Switzerland). The homogenate was centrifuged for 80 minutes at 100,000g (30,000 rpm in an F50L rotor) at 4°C. After removal of the fatty layer, the resultant supernatant was centrifuged for 1 hour at 100,000g (30,000 rpm in an F50L rotor; Thermo Scientific, Perth, UK). After ultracentrifugation, the supernatant (cytosolic fraction) was retained and the pellet (microsomal fraction) was resuspended in KCl buffer containing 0.25 M sucrose. The protein content of the microsomal and cytosolic fractions was quantified by bicinchoninic acid assay (Thermo Scientific).

Glutathione-Affinity Chromatography.

The recombinant mouse glutathione S-transferase p1 (mGstp1) and GST mixture from liver cytosol (mouse and human) were purified using a GSTrap FF affinity column (1 ml; Amersham Biosciences AB, Uppsala, Sweden) according to the manufacturer’s protocol. Briefly, the column was equilibrated with five column volumes of binding buffer (phosphate-buffered saline, pH 7.3). The sample was filtered through a 0.45 µm filter and loaded onto the column at a flow rate of 1 ml/min, followed by washing with five columns of binding buffer, and then the bound protein was eluted by adding five column volumes of elution buffer (50 mM Tris-HCl, 10 mM reduced GSH, pH 8.0, at a flow rate of 1 ml/min). The eluted protein was collected and analyzed by SDS-PAGE. The proteins were concentrated and buffer exchanges were performed using a 10 kDa Nanosep centrifugal device (previously conditioned by wetting with 0.5 ml of distilled water and followed by drying by centrifugation at 14,000g for 10 minutes at 4°C) to 50 mM Tris-HCl, pH 7.4. The retained protein residues were quantitatively dislodged from the membranes by using 100 µl aliquots of 50 mM Tris-HCl, pH 7.4. Protein concentration was then quantified by a bicinchoninic acid assay using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Somerset, NJ) according to the manufacturer’s instructions.

In Vitro Metabolism.

All incubations were performed at 37°C and 300 rpm in a thermomixer. Human cDNA-expressed P450 isoenzymes coexpressed with human NADPH P450 oxidoreductase (see Supplemental Fig. 1 for CYP:oxidoreductase ratio data) were carefully thawed on ice prior to the experiment. Ponatinib (50 µM with 0.25% dimethylsulfoxide) was mixed with human P450 isoenzymes (100 nM) in 100 mM potassium phosphate buffer (pH 7.4) containing 3.3 mM MgCl2 supplemented with or without GSH and a GST mixture from mouse or human liver cytosol. After 5-minute preincubation at 37°C, the incubation reactions were initiated by addition of a NADPH regenerating system (final concentration: 1.3 mM NADPH, 4 mM glucose-6-phosphate, and 2 unit/ml glucose-6-phosphate dehydrogenase). After 5–120 minutes, an aliquot of 100 µl of reaction mixture was quenched with same volume of cold acetonitrile containing 400 ng/ml of triazolam as the internal standard. The samples were then centrifuged at 3000g for 55 minutes at 4°C. An aliquot of the supernatant fraction was analyzed by liquid chromatography (LC)–tandem mass spectrometry (MS), i.e., LC-MS/MS.

In Vivo Studies.

All animal work was carried out on 8- to 12-week-old male mice. 3-Methylcholanthrene (3-MC) was suspended in corn oil at 4 mg/ml for administration by intraperitoneal injection at 40 mg/kg (10 μl/g body weight) daily for 3 days for hCYP1A1/2 mice. TCDD was suspended in corn oil at 1 µg/ml for administration by intraperitoneal injection at 10 µg/kg (10 μl/g body weight) daily for 3 days for wild-type (WT) mice. For pharmacokinetic (PK) analyses, ponatinib was first dissolved in 25 mM citrate buffer (pH 2.5) at a concentration of 4 mg/ml for immediate administration by oral gavage at a final dose of 40 mg/kg. For blood sample collection, 10 μl of whole blood was withdrawn from the tail vein at the indicated time points. Samples were immediately added to a tube containing heparin solution (10 μl, 15 IU/ml), put into liquid nitrogen, and then stored at −80°C until processing. On the day of analysis, acetonitrile (80 µl containing 200 ng/ml triazolam) was added to thawed samples, which were shaken for 15 minutes, centrifuged for 10 minutes at 16,000g, and analyzed. Plasma ponatinib concentrations were determined by an internal standard LC-multiple reactions monitoring (MRM) method using calibration standards prepared in blank mouse plasma. Feces were collected in Tecniplast mouse metabolic cages (Tecniplast, Leicester, UK); mice were housed singly with free access to food and water for up to 24 hours after administration of ponatinib dose. To measure fecal GSH ponatinib metabolites each sample was diluted by water (1:3 v/v) and homogenized with a mortar and pestle. An aliquot of 0.25 g was extracted with 1 ml of 80% methanol for 30 minutes on a vortex evaporator (Labconco, Kansas City, MO). After centrifugation (30 minutes at 4000g), the solvent of a 800 μl aliquot of the supernatant was removed by speed vacuum, followed by reconstitution in 500 μl methanol and water (50/50, v/v), and analyzed by LC-MRM.

Western Immunoblotting Analyses.

Liver microsomal samples were adjusted to 1 mg/ml in LDS Lithium Dodecyl Sulfate sample buffer (Life Technologies) and subjected to SDS-PAGE and immunoblotting as previously described (MacLeod et al., 2015). Primary antibodies were used as follows: anti-CYP1A1 (1:1000; AB1258; Millipore, Watford, United Kingdom) and Cyp1a (1:1000) (Forrester et al., 1992). Anti-GRP78 (1:1000; ab21685; Abcam (Cambridge, UK)) was used as the loading control. Immunoreactive proteins were detected using polyclonal goat anti-rabbit or anti-mouse horseradish peroxidase immunoglobulins as secondary antibodies (Dako, Ely, United Kingdom) and were visualized using Immobilon chemiluminescent substrate (Millipore) and a Fujifilm LAS-3000 mini-imaging system (Fujifilm UK Ltd., Bedford, United Kingdom).

LC-MS-MRM Analysis.

Analysis of in vitro incubation and in vivo blood PK samples was carried out by ultra-performance LC-MS/MS using the Waters Acquity UPLC (Micromass, Manchester, United Kingdom) and Micromass Quattro Premier Mass Spectrometer with electrospray ionization. The chromatography was performed using a C18 column (Kinetex 1.7 µ 100 A; 50 × 2.1 mm; Phenomenex, Macclesfield, United Kingdom) at a temperature of 45°C with mobile phases of 0.1% formic acid (A) and acetonitrile and 0.1% formic acid (B). A gradient at a flow rate of 0.5 ml/min was run over 3 minutes as follows: 0–0.5 minutes, 95% A; 0.5–0.75 minutes, 95%–67.5% A; 0.75–1.50 minutes, 67.5% A, 1.50–2.00 minutes, 67.5%–50% A; 2.00–2.50 minutes, 50%–5% A; and then returning to the initial conditions for a final 0.5 minutes. The cone voltage and collision energy were optimized for each substrate and MRM data were acquired (Supplemental Table 1).

liquid chromatography eletcrospray ionization/multi-stage mass spectrometry (LC-MS-MSn) Analysis.

The LC-MS/MS system consisted of a Waters Alliance 2690 high-performance LC system (Waters, Milford, MA) and a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific) with an electrospray ionization interface. The chromatography was performed on a XB-18 column (Kinetex 50 × 2.1 mm, 2.6 µm particle size; Phenomenex) at a temperature of 40°C. Analytes were eluted from the column with 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). A gradient at a flow rate of 0.4 ml/min was run over 18 minutes as follows: 0–0.5 minutes, 95%–80% A; 0.5–10 minutes, 80%–5% A; 10–12.5 minutes, 5% A; 12.5–14 minutes, 5%–95% A; and 14–18 minutes, 95% A. The mass spectrometer was tuned to optimal conditions for ponatinib and was operated in a data-independent acquisition mode, which consisted of two scan events: a survey full scan (150–600 m/z) at a resolution of 30 K Orbitrap and multi-stage mass spectrometry (MSn) scan at an ion trap. The product ions were generated by collision-induced dissociation mode.

Bioactivation of Ponatinib by Human Recombinant CPY1A1 in the Presence of mGstp1.

To generate protein adducts of oxidative ponatinib metabolites with mGstp1, incubations were conducted with a reaction mixture of human recombinant CYP1A1 (100 nmol) in Escherichia coli membrane, 10 µg/ml mGstp1, and 50 µM ponatinib (0.5 µl 20 mM in acetonitrile) as substrate, in a final volume of 200 µl 100 mM potassium phosphate buffer (pH 7.4). The incubation was started by the addition of a NADPH-regenerating system (final concentration: 1.3 mM NADPH, 4 mM glucose-6-phosophate, 2 U/ml glucose-6-phosphate dehydrogenase, and 3.3 mM potassium phosphate) and allowed to proceed at 37°C for 80 minutes. The reaction was terminated by cooling on ice, and the E. coli membrane containing human recombinant CYP1A1 was removed by ultracentrifugation at 41,000g at 4°C for 80 minutes. The supernatant was further filtered through a Pall Nanosep 10 K OMEGA (PN OD010C34) filter to remove unbound ponatinib and its metabolites. The solvent was exchanged to 50 mM ammonium bicarbonate and further concentrated to 100 µl.

Aliquots of the solution (10 µl) were mixed with 10 μl of 4× NuPAGE lithium dodecyl sulfate loading buffer (Invitrogen, Carsbad, CA) by incubation at 95°C for 5 minutes and then subjected to SDS-PAGE on a NuPAGE Novex 10% Bis-Tris mini gel (Invitrogen NP0341BOX). After electrophoresis at a constant 180 V for 30 minutes, gels were stained with Coomassie Blue. Bands (20–25 kDa) containing mGstp1 were cut from the gel, and after removing the Coomassie Blue from the gel by adding 100 mM ammonium bicarbonate/acetonitrile (1:1, v/v) and subsequently dehydrating with 100% acetonitrile, the solvent was removed from the gel pieces under vacuum. The residue was resuspended in 0.01 μg/μl MS grade trypsin (Promega, Madison, WI) in 25 mM ammonium bicarbonate and incubated at 37°C overnight. Peptides were extracted by adding buffer [1:2 (v/v) 5% formic acid/acetonitrile] and evaporated by speed vacuum (Shevchenko et al., 2006). Samples were redissolved for LC-MS/MS analysis in 20 μl of 5% acetonitrile containing 0.1% trifluoroacetic acid.

Data Analysis.

In the present study, the absolute concentrations of the metabolites in the incubation mixture could not be determined because of the lack of authentic standards. Therefore, the relative activity of the P450s was presented by comparing the concentration of the metabolite in a sample with the concentration of the same metabolite in the sample that had the highest response under the same experimental condition (Yu et al., 2010). The relative activity of the P450s toward metabolite formation could be calculated according to the ratio of the metabolite concentration to that in the sample with highest mass response. The PK parameters of in vivo data were calculated with a simple noncompartmental model using the WinNonLin software, version 4.1 (Pharsight (Certara, Cambridge, UK)) and are shown with the S.D. values. The P values were calculated using an unpaired t test; *P < 0.05, **P < 0.01, ***P < 0.001.

Results

Ponatinib Biotransformation and Formation of a GSH Adduct by Human Recombinant P450 Enzymes.

The contribution of individual P450 enzymes to ponatinib biotransformation was evaluated using a panel of 11 human recombinant P450 enzymes (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYPC8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP2E1). Ponatinib was principally metabolized via CYP3A4 and CYP1A1, as measured by the disappearance of the parent drug (Fig. 1A). CYP3A4 had the highest activity in the formation of both the N-desmethyl (AP24567) and N-oxide (AP24734) metabolites (Fig. 1, B and C), with lesser contributions from CYP2C8 and CYP2D6. It should be noted that in the case of CYP2C8 and CYP2D6, the P450/P450 oxidoreductase ratio was considerably lower than for CYP3A4. In the event that P450 oxidoreductase is rate limiting in these samples, the actual rates of metabolism could be higher. In the case of CYP1A1, metabolism of ponatinib resulted in four different monohydroxylated products (P-OH, m/z 549) with retention times of 5.00 minutes (P-OH-1), 5.60 minutes (P-OH-2), 5.94 minutes (P-OH-3), and 7.07 minutes (P-OH-4), as well as a number of dihydroxylated products (see Fig. 2 and Supplemental Material for a more detailed description of the metabolites formed). The major metabolites were 2- and 4-hydroxyponatinib. These metabolites were also produced, to a lesser degree, by CYP1A2 and CYP1B1. The formation of hydroxylated metabolites could be a consequence of epoxidation reactions, a characteristic activity of CYP1A1. For this reason, we also carried out incubations in the presence of GSH. Indeed, this resulted in the formation of a ponatinib-GSH (P-GSH) conjugate. The P-OH-2 and P-OH-4 metabolites were not detected in incubations containing GSH, whereas P-OH-1 and P-OH-3 were unchanged (Fig. 2A, middle), suggesting that epoxidation had taken place at the site of these hydroxylation reactions. In addition, the formation of the dihydroxylation products was significantly reduced when GSH was added to the incubation (Fig. 2B, middle). Generation of P-GSH was not detected with any other P450 isoforms.

Fig. 1.
Fig. 1.

Ponatinib metabolites and GSH adduct mediated by recombinant human P450 isoforms. Recombinant human P450 isoforms were incubated with ponatinib, and parent drug, metabolites, and conjugate determined as described in Materials and Methods. (A) Disappearance of ponatinib. (B) Formation of N-demethylation (AP24567). (C) Formation of N-oxidation (AP24734). (D) Formation of GSH adduct (P-GSH).

Fig. 2.
Fig. 2.

Reversed-phase LC selected ion chromatograms of ponatinib oxidation and GSH adduct mediated by CYP1A1. Ponatinib (50 µM) was incubated with CYP1A1 in the presence of an NADPH regeneration system as described in Materials and Methods. (A) Formation of P-OH (m/z 549.22) (top) in the absence of GSH and mGstp1, and (middle) in the presence of 5 mM GSH and 10 µg/ml mGstp1; (bottom) formation of P-GSH (m/z, 2+, 419.65) in the presence of 5 mM GSH and 10 µg/ml mGstp1. (B) Formation of P-2OH (m/z 565.22) (top) in the absence of GSH and mGstp1 and (middle) in the presence of 5 mM GSH and 10 µg/ml mGstp1; (bottom) Formation of P-OH-GSH (m/z, 2+, 427.65) in the presence of 5 mM GSH and 10 µg/ml mGstp1.

The MS spectrum of P-GSH revealed a molecular ion [M+2H]2+ of m/z 419.7, suggesting a GSH adduct with the addition of the sulfhydryl nucleophile to ponatinib (Supplemental Fig. 2A). Fragmentation of P-GSH molecular ions resulted in neutral loss of 75 and 129, corresponding to elimination of the glycine and pyroglutamate of GSH, respectively (Supplemental Fig. 2B), but yielded no information on the specific site of ponatinib modification. MS analysis of the fragments containing four monohydroxylated products clearly indicated that CYP1A1-mediated oxidation had occurred on the partial structure of ring A, linker B, or ring C, and that GSH conjugation had occurred on ring C (Supplemental Figs. 3–5).

Glutathione S-Transferases Catalyze the Formation of P-GSH Conjugates.

The action of electrophiles with GSH is catalyzed by GST (Hayes et al., 2005; Tew and Townsend, 2012). Therefore, we investigated this possibility through the addition of recombinant GST or GST mixtures to the incubation system. The formation of P-OH-2 and P-OH-4 was linear for at least 20 minutes and with differing concentrations of recombinant CYP1A1 protein up to 10 nM at 3 µM ponatinib. Incubations were therefore routinely carried out for 20 minutes with 10 nM recombinant CYP1A1 protein. The formation of the P-GSH conjugate was significantly increased by the addition of recombinant mGstp1 protein up to 20 µg/ml (Fig. 3A). The fact that this reaction was saturated at 20 µg/ml suggests that the rate of hydroxylation was rate limiting in this experiment. Consistent with the data shown in Fig. 2, the formation of P-OH-2 and P-OH-4 was inversely related to the formation of the P-GSH conjugate (Fig. 3, B and C), whereas the formation of P-OH-1 was not affected by the addition of mGstp1 (Fig. 3D).

Fig. 3.
Fig. 3.

Effect of GST and GSH concentrations on the formation of monooxidation product and P-GSH. Ponatinib was incubated with CYP1A1 as described in Materials and Methods. (A) Formation of P-GSH, (B) formation of P-OH-2, (C) formation of P-OH-4, and (D) formation P-OH-1 in the presence of GSH and recombinant mGstp1 (black circles) or bovine serum albumin (BSA) (white square). (E) Formation of P-GSH in the presence of GSH and recombinant mGstp1 (black bar) or BSA (white bar). (F) Formation of P-GSH in the presence of GSH and GST fractions from WT, Gstp1/2 NULL mice, or human liver cytosol.

The dependence of GST-mediated P-GSH conjugate on GSH concentration is shown in Fig. 3E. At a GSH concentration of 5 mM, the rate of the mGstp1-catalyzed P-GSH conjugate formation was approximately double the rate of the nonenzymic reaction. However, at a GSH concentration of 0.05 mM the rate of the enzyme-catalyzed conjugate was increased more than 40-fold compared with the nonenzymic control (68% versus 1.4%, respectively). These differences were also reflected in an inverse manner by the formation of P-OH-2 and P-OH-4 (data not shown). Therefore, the effect of mGstp1 on the rate of P-GSH-conjugated formation is greatest at the lowest GSH concentration, consistent with a previous report that the covalent binding rate of an acetaminophen-GSH conjugate is greatest at low GSH concentrations (Rollins and Buckpitt, 1979).

To further investigate the role of GSTs in the formation of the P-GSH conjugate, Gst/GST mixtures were purified from Gstp1WT and Gstp1/2NULL mice and human liver through a GSTrap FF affinity column and incubated with ponatinib. Compared with the activity of the Gst mixture from mouse Gstp1WT liver cytosol (100%), the formation of P-GSH was significantly reduced in both Gstp1/2NULL (56%) mice indicating that, in agreement with the data obtained with the recombinant enzyme, Gstp is responsible for ∼60% of the murine hepatic conjugating activity. The activity of human liver GSTs was also lower (28%), which could be ascribed to the fact that human hepatocytes from healthy individuals do not express glutathione S-transferase P (GSTP) (Fig. 3F).

Induction of CYP1A1 Markedly Alters Ponatinib Exposure and Induces P-GSH Conjugate Excretion In Vivo.

To study the contribution of CYP1A1 to the metabolism and disposition of ponatinib in vivo, WT, and humanized hCYP1A1/1A2 mice were administered the aryl hydrocarbon receptor activators TCDD or 3-MC for 3 days prior to ponatinib administration. In WT mice treated with TCDD an 87% reduction in the AUC0–8 hours value and a significant decrease (62%) in the ponatinib half-life were observed (Fig. 4A; Table 1). In hCYP1A1/1A2 mice treated with 3-MC, significant reductions in both the AUC0–8 hours (54%) and half-life (67%) values for ponatinib were also observed (Fig. 4B; Table 1). In addition, significant amounts of the P-GSH conjugate were detected in fecal samples from 3-MC-treated hCYP1A1/1A2 mice (Fig. 4F). This metabolite was not detectable in control (vehicle-treated) animals treated with ponatinib (Fig. 4E). The absolute level of the P-GSH conjugate formed could not be determined because relevant standards were not available.

Fig. 4.
Fig. 4.

Activation of the aryl hydrocarbon receptor alters ponatinib pharmacokinetics and formation of GSH adduct in vivo. (A) PK profiles of ponatinib in WT mice treated with vehicle (circles; n = 3) or TCDD (squares; n = 3). (B) PK profiles of ponatinib in huCYP1A1/2 mice treated with vehicle (circles; n = 3) and 3-MC (squares; n = 3). (C) Western blots of hepatic microsomal fractions from WT mice dosed with either vehicle or TCDD. (D) Western blots of hepatic microsomal fractions from huCYP1A1/2 mice dosed with either vehicle or 3-MC. (E) LC-MRM chromatogram of P-GSH in feces (up to 24 hours) from ponatinib-treated humanized CYP1A1/2 mice. (F) LC-MRM chromatogram of P-GSH in feces (up to 24 hours) from ponatinib-treated humanized CYP1A1/2 mice pretreated with 3-MC. Apparent PK parameters are detailed in Table 1.

View this table:
TABLE 1

Pharmacokinetic parameters of ponatinib in WT mice and hCYP1A1/2 pre-treated with TCDD or 3-MC

The PK parameters were calculated as outlined in Materials and Methods. The P values were calculated using an unpaired t test: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.

Ponatinib Forms an Adduct with mGstp1 in the Presence of CYP1A1.

It has often been observed that the conjugation of electrophiles by Gstp1 also results in covalent modification of Gstp1 itself. To investigate this possibility, tryptic peptides obtained following incubations of ponatinib with CYP1A1 and Gstp1 were analyzed and two different adducts of Gstp1 were identified (Supplemental Table 2). Further MS analysis demonstrated that ponatinib-Gstp adducts had been formed on Cys-14 and Cys-47, but not on Cys-167.

Discussion

Ponatinib is used to treat CML patients who have relapsed following imatinib therapy (Holyoake and Vetrie, 2017). Although effective, the use of this drug is compromised by a number of serious side effects including vascularitis, pancreatitis, and hepatotoxicity (Cortes et al., 2013; Lipton et al., 2016). To obtain greater insights into pathways of ponatinib metabolism and toxicity we investigated the enzymes involved in its disposition and the metabolites produced by different human P450 enzymes (Fig. 5). Studies were carried out in vitro using humanized mouse models. In agreement with the published literature, CYP3A4 was the major hepatic P450 enzyme involved in the production of the N-desmethyl (AP24576) and N-oxide (AP24734) metabolites (Narasimhan et al., 2013). However, a number of different metabolites were produced by CYP1A1. Surprisingly, this potentially important pathway of ponatinib metabolism has, to our knowledge, not been previously reported. The metabolites produced by CYP1A1 were reduced by the addition of GSH to the incubation medium, suggesting that reactive electrophilic products had been formed, probably epoxides. Epoxides can be inactivated by a number of enzymes, including GSTs and epoxide hydrolases (Seidegård and Ekström, 1997). In support of epoxide formation, we have shown that the formation of the GSH conjugate of ponatinib is greatly increased by the addition of both murine and human GST. In particular, we have demonstrated that Gstp has significant activity in this regard. If an epoxide was the electrophilic intermediate, it might have been anticipated that two GSH adducts would have been formed. This may be the case, but not observed, if the two adducts were not separated by ultra-performance LC. Also, the MS fragmentation pattern would unfortunately not distinguish the sites of glutathionylation. In addition, it is feasible that one site of glutathionylation was preferred due to steric differences, or the reaction catalyzed by Gstp generates a site-specific product. The formation of reactive epoxides from ponatinib and their inactivation by Gstp has a number of possible implications. Epoxides are chemically reactive and can react covalently with both DNA and proteins to cause mutations and toxicity (Hinson and Roberts, 1992; Boelsterli, 1993; Swenberg et al., 2011). The nucleophilic sites in proteins include cysteine residues, consistent with our finding here that metabolic activation of ponatinib resulted in cysteine conjugates of Gstp1. The cysteine residues, especially Cys-47 of human enzyme GSTP1-1, have been found to be targeted by many electrophilic compounds resulting from P450 metabolism such as acetaminophen, clozapine, and troglitazone (Orton and Liebler, 2007; Tew, 2007; Boerma et al., 2011, 2012; Zhang et al., 2014). When ponatinib was incubated with Gstp1 in the presence of recombinant human CYP1A1, adducts of ponatinib were observed on Cys-14 and Cys-47. The fact that no adducts of ponatinib to Cys-169 were observed in this study may be due to its low reactivity, or perhaps more likely to the relative insensitivity of our methodology in detecting Cys-169-containing tryptic peptides. It would have been interesting to establish whether the addition of epoxide hydrolase to the incubation reduced the formation of the GSH conjugate. However, we have been unable to source any functionally active epoxide hydrolase, and while we believe that epoxide formation is the initial oxidation step, this remains to be formally established.

Fig. 5.
Fig. 5.

Ponatinib structure and disposition. The structure of ponatinib is shown, along with its known metabolites and pathways of disposition. The involvement of human P450 isoforms is also indicated.

Therefore, it is possible that the formation of reactive epoxides from ponatinib contributes to the side effects associated with its clinical use. CYP1A1 is a highly inducible enzyme and unlike many other P450s can be expressed in most tissues (Hussain et al., 2014). Metabolic activation could therefore, in principle, occur in all of the reported ponatinib target tissues. CYP1A1 levels are constitutively very low, but are highly inducible on activation of the aryl hydrocarbon receptor by compounds including polycyclic aromatic hydrocarbons found in cigarette smoke (Schiwy et al., 2015). It is interesting to note that hypertension or vaso-occlusive disease observed following ponatinib administration has been associated with smoking (Jain et al., 2015). This potential association is therefore worthy of further epidemiologic studies. If reactive metabolites of ponatinib are involved in its toxicity this could be reduced using inhibitors of CYP1A1. It is worthy of note that the reactive metabolites of ponatinib are also inactivated by conjugation with GSH, mediated at least in part by GSTP. GSTP is expressed in most cell types and indeed in many tumors resistant to anticancer drugs (Henderson et al., 2011, 2014; Tew and Townsend, 2011). Therefore, cellular GSH and GSTP status may also be an important determinant of ponatinib side effects.

In addition to possible involvement in ponatinib side effects, or indeed as a determinant of intratumoral drug concentration, CYP1A1 and CYP1A2 may also contribute to ponatinib exposure since plasma levels and half-life were significantly changed in CYP1A1/1A2 humanized mice treated with aryl hydrocarbon receptor activators (Fig. 4). The PK parameters obtained using this model showed comparable plasma half-life (t1/2, 13.9 hours) to that in human (∼24 hours), whereas the t1/2 value was 6.2 hours in WT mice demonstrating the strengths of using humanized models for such studies.

CYP1 family enzymes, especially CYP1A1 and CYP1B1, are overexpressed in myeloblastic and lymphoid cell lines such as U937, BALL-1, and HL-60 (Nagai et al., 2002). The potential expression of these enzymes in CML cells may also be a factor in drug efficacy, or indeed drug resistance. Indeed, our findings provide a mechanistic rationale for the recent report that CML patients that are smokers are at increased risk of disease progression and premature death (Lauseker et al., 2017).

Acknowledgments

We thank Julia Carr, Lulu Acosta, and Tanya Frangova for assistance with animal work. We thank Dr. Kenneth Macleod and Yury Kapelyukh for useful discussions. We also acknowledge Taconic Biosciences (Cologne, Germany) for supplying the mouse lines used in this study.

Authorship Contributions:

Participated in research design: Lin, Kostov, Huang, Henderson, Wolf.

Conducted experiments: Lin, Kostov, Huang.

Contributed new reagents or analytic tools: Lin, Kostov, Huang.

Performed data analysis: Lin, Kostov, Huang.

Wrote or contributed to the writing of the manuscript: Lin, Huang, Henderson, Wolf.

Footnotes

Abbreviations

AUC
area under the curve
CML
chronic myeloid leukemia
GSH
glutathione
GST
glutathione S-transferase
GSTP
glutathione S-transferase P
LC
liquid chromatography
3-MC
3-methylcholanthrene
mGstp1
mouse glutathione S-transferase p1
MRM
multiple reactions monitoring
MS
mass spectrometry
P-GSH
ponatinib-glutathione
PK
pharmacokinetic
P450
cytochrome P450
TCDD
2,3,7,8-tetrachlorodibenzodioxin
WT
wild type

This is an open access article distributed under the CC BY Attribution 4.0 International license.

References

  1. ↵
    1. Baillie TA
    (2006) Future of toxicology–metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889–893.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Boelsterli UA
    (1993) Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury. Drug Metab Rev 25:395–451.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Boerma JS,
    2. Dragovic S,
    3. Vermeulen NP, and
    4. Commandeur JN
    (2012) Mass spectrometric characterization of protein adducts of multiple P450-dependent reactive intermediates of diclofenac to human glutathione-S-transferase P1-1. Chem Res Toxicol 25:2532–2541.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Boerma JS,
    2. Vermeulen NP, and
    3. Commandeur JN
    (2011) Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites. Chem Res Toxicol 24:1263–1274.
    OpenUrlPubMed
  5. ↵
    1. Cortes JE,
    2. Kantarjian H,
    3. Shah NP,
    4. Bixby D,
    5. Mauro MJ,
    6. Flinn I,
    7. O’Hare T,
    8. Hu S,
    9. Narasimhan NI,
    10. Rivera VM, et al.
    (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075–2088.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Cortes JE,
    2. Kim DW,
    3. Pinilla-Ibarz J,
    4. le Coutre P,
    5. Paquette R,
    6. Chuah C,
    7. Nicolini FE,
    8. Apperley JF,
    9. Khoury HJ,
    10. Talpaz M, et al., and PACE Investigators
    (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783–1796.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Forrester LM,
    2. Henderson CJ,
    3. Glancey MJ,
    4. Back DJ,
    5. Park BK,
    6. Ball SE,
    7. Kitteringham NR,
    8. McLaren AW,
    9. Miles JS,
    10. Skett P, et al.
    (1992) Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281:359–368.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Frankfurt O and
    2. Licht JD
    (2013) Ponatinib—a step forward in overcoming resistance in chronic myeloid leukemia. Clin Cancer Res 19:5828–5834.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hayes JD,
    2. Flanagan JU, and
    3. Jowsey IR
    (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51–88.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Henderson CJ,
    2. McLaren AW, and
    3. Wolf CR
    (2014) In vivo regulation of human glutathione transferase GSTP by chemopreventive agents. Cancer Res 74:4378–4387.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Henderson CJ,
    2. Ritchie KJ,
    3. McLaren A,
    4. Chakravarty P, and
    5. Wolf CR
    (2011) Increased skin papilloma formation in mice lacking glutathione transferase GSTP. Cancer Res 71:7048–7060.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Hinson JA and
    2. Roberts DW
    (1992) Role of covalent and noncovalent interactions in cell toxicity: effects on proteins. Annu Rev Pharmacol Toxicol 32:471–510.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Holyoake TL and
    2. Vetrie D
    (2017) The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood 129:1595–1606.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Huang WS,
    2. Metcalf CA,
    3. Sundaramoorthi R,
    4. Wang Y,
    5. Zou D,
    6. Thomas RM,
    7. Zhu X,
    8. Cai L,
    9. Wen D,
    10. Liu S, et al.
    (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenylbenzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 53:4701–4719.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hussain T,
    2. Al-Attas OS,
    3. Al-Daghri NM,
    4. Mohammed AA,
    5. De Rosas E,
    6. Ibrahim S,
    7. Vinodson B,
    8. Ansari MG, and
    9. El-Din KI
    (2014) Induction of CYP1A1, CYP1A2, CYP1B1, increased oxidative stress and inflammation in the lung and liver tissues of rats exposed to incense smoke. Mol Cell Biochem 391:127–136.
    OpenUrl
  16. ↵
    1. Jain P,
    2. Kantarjian H,
    3. Jabbour E,
    4. Gonzalez GN,
    5. Borthakur G,
    6. Pemmaraju N,
    7. Daver N,
    8. Gachimova E,
    9. Ferrajoli A,
    10. Kornblau S, et al.
    (2015) Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol 2:e376–e383.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Kalgutkar AS and
    2. Dalvie D
    (2015) Predicting toxicities of reactive metabolite-positive drug candidates. Annu Rev Pharmacol Toxicol 55:35–54.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Lauseker M,
    2. Hasford J,
    3. Saussele S,
    4. Kremers S,
    5. Kraemer D,
    6. Lindemann W,
    7. Hehlmann R,
    8. Pfirrmann M, and German CML Study Group
    (2017) Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. Cancer 123:2467–2471.
    OpenUrl
  19. ↵
    1. Lipton JH,
    2. Chuah C,
    3. Guerci-Bresler A,
    4. Rosti G,
    5. Simpson D,
    6. Assouline S,
    7. Etienne G,
    8. Nicolini FE,
    9. le Coutre P,
    10. Clark RE, et al., and EPIC investigators
    (2016) Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 17:612–621.
    OpenUrlCrossRefPubMed
  20. ↵
    1. MacLeod AK,
    2. McLaughlin LA,
    3. Henderson CJ, and
    4. Wolf CR
    (2015) Activation status of the pregnane X receptor influences vemurafenib availability in humanized mouse models. Cancer Res 75:4573–4581.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Miller GD,
    2. Bruno BJ, and
    3. Lim CS
    (2014) Resistant mutations in CML and Ph+ALL—role of ponatinib. Biologics 8:243–254.
    OpenUrl
  22. ↵
    1. Nagai F,
    2. Hiyoshi Y,
    3. Sugimachi K, and
    4. Tamura HO
    (2002) Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull 25:383–385.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Narasimhan NI,
    2. Dorer DJ,
    3. Niland K,
    4. Haluska F, and
    5. Sonnichsen D
    (2013) Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol 53:974–981.
    OpenUrl
  24. ↵
    1. O’Hare T,
    2. Shakespeare WC,
    3. Zhu X,
    4. Eide CA,
    5. Rivera VM,
    6. Wang F,
    7. Adrian LT,
    8. Zhou T,
    9. Huang WS,
    10. Xu Q, et al.
    (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401–412.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Orton CR and
    2. Liebler DC
    (2007) Analysis of protein adduction kinetics by quantitative mass spectrometry: competing adduction reactions of glutathione-S-transferase P1-1 with electrophiles. Chem Biol Interact 168:117–127.
    OpenUrlPubMed
  26. ↵
    1. Razzak M
    (2013) Haematology: ponatinib—the next TKI challenge. Nat Rev Clin Oncol 10:65.
    OpenUrl
  27. ↵
    1. Rollins DE and
    2. Buckpitt AR
    (1979) Liver cytosol catalyzed conjugation of reduced glutathione with a reactive metabolite of acetaminophen. Toxicol Appl Pharmacol 47:331–339.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Schiwy A,
    2. Brinkmann M,
    3. Thiem I,
    4. Guder G,
    5. Winkens K,
    6. Eichbaum K,
    7. Nüßer L,
    8. Thalmann B,
    9. Buchinger S,
    10. Reifferscheid G, et al.
    (2015) Determination of the CYP1A-inducing potential of single substances, mixtures and extracts of samples in the micro-EROD assay with H4IIE cells. Nat Protoc 10:1728–1741.
    OpenUrl
  29. ↵
    1. Seidegård J and
    2. Ekström G
    (1997) The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 105 (Suppl 4):791–799.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Shevchenko A,
    2. Tomas H,
    3. Havlis J,
    4. Olsen JV, and
    5. Mann M
    (2006) In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1:2856–2860.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Swenberg JA,
    2. Lu K,
    3. Moeller BC,
    4. Gao L,
    5. Upton PB,
    6. Nakamura J, and
    7. Starr TB
    (2011) Endogenous versus exogenous DNA adducts: their role in carcinogenesis, epidemiology, and risk assessment. Toxicol Sci 120 (Suppl 1):S130–S145.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Tew KD
    (2007) Redox in redux: emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem Pharmacol 73:1257–1269.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Tew KD and
    2. Townsend DM
    (2011) Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification. Drug Metab Rev 43:179–193.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Tew KD and
    2. Townsend DM
    (2012) Glutathione-S-transferases as determinants of cell survival and death. Antioxid Redox Signal 17:1728–1737.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Yu J,
    2. Brown DG, and
    3. Burdette D
    (2010) In vitro metabolism studies of nomifensine monooxygenation pathways: metabolite identification, reaction phenotyping, and bioactivation mechanism. Drug Metab Dispos 38:1767–1778.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Zhang J,
    2. Grek C,
    3. Ye ZW,
    4. Manevich Y,
    5. Tew KD, and
    6. Townsend DM
    (2014) Pleiotropic functions of glutathione S-transferase P. Adv Cancer Res 122:143–175.
    OpenUrl
  37. ↵
    1. Zhou T,
    2. Commodore L,
    3. Huang WS,
    4. Wang Y,
    5. Thomas M,
    6. Keats J,
    7. Xu Q,
    8. Rivera VM,
    9. Shakespeare WC,
    10. Clackson T, et al.
    (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77:1–11.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleChemotherapy, Antibiotics, and Gene Therapy

CYP1A1-Dependent Ponatinib Metabolism

De Lin, Rumen Kostov, Jeffrey T.-J. Huang, Colin J. Henderson and C. Roland Wolf
Journal of Pharmacology and Experimental Therapeutics October 1, 2017, 363 (1) 12-19; DOI: https://doi.org/10.1124/jpet.117.243246
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement